Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks
Latest Information Update: 08 Jun 2022
At a glance
- Drugs Bevacizumab (Primary) ; Aflibercept
- Indications Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms SCORE2
- 01 May 2022 Results of a post hoc outcome analysis published in the JAMA Ophthalmology
- 01 May 2022 Results of post-hoc analysis assessing macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab, published in the Graefes Archive for Clinical and Experimental Ophthalmology.
- 24 May 2021 Status changed from active, no longer recruiting to completed.